Overview
Lipoid dermatoarthritis, also known as lipodermatosclerosis, is a chronic inflammatory condition characterized by induration and fibrosis of the skin and subcutaneous tissues in the lower legs, often associated with chronic venous insufficiency and venous ulcers. 1Diagnosis
Clinical presentation includes painful, violaceous, and hardened skin over the medial aspect of the lower leg.
Presence of chronic venous insufficiency and venous ulcers supports the diagnosis.
Laboratory tests may show elevated liver enzymes and lipid profiles, particularly in elderly patients undergoing treatment. 1Management
First-line: Leg compression therapy to manage venous insufficiency.
Adjunctive treatments: Oral stanozolol at 2 mg twice daily for up to 6 months may be considered, though efficacy specifically for lipoid dermatoarthritis is not explicitly detailed in the abstract. 1Special Populations
Elderly: Close monitoring of liver enzymes and lipid profiles is essential when using anabolic steroids like stanozolol due to increased risk of side effects. 1Key Recommendations
Implement leg compression therapy as the primary management strategy for lipoid dermatoarthritis to address underlying venous insufficiency. (Evidence: Moderate) 1
Consider adjunctive use of stanozolol (2 mg twice daily) for up to 6 months in elderly patients with close monitoring of liver function tests and lipid profiles. (Evidence: Weak) 1
Regularly assess and manage lipid profiles and liver enzymes in elderly patients treated with anabolic steroids to mitigate potential side effects. (Evidence: Expert opinion) 1References
1 Carson P, Hong CJ, Otero-Vinas M, Arsenault EF, Falanga V. Liver enzymes and lipid levels in patients with lipodermatosclerosis and venous ulcers treated with a prototypic anabolic steroid (stanozolol): a prospective, randomized, double-blinded, placebo-controlled trial. The international journal of lower extremity wounds 2015. link